Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence

Ayaka Sato1,2, Takehiko Sakai1, Takuji Iwase1, Fumiko Kano1, Kiyomi Kimura1,3, Akiko Ogiya1, Mitsuru Koizumi4, Masahiko Tanabe2, Rie Horii5,6, Futoshi Akiyama6, Takayuki Ueno1* and Shinji Ohno1

Abstract

Background: This study aimed to evaluate the impact of previous local treatment on lymphatic drainage patterns in ipsilateral breast tumor recurrence (IBTR) based on our data on re-operative sentinel lymph node biopsy (re-SLNB) for IBTR.

Methods: Between April 2005 and December 2016, re-SLNB using lymphoscintigraphy with Tc-99 m phytate was performed in 136 patients with cN0 IBTR. Patients were categorized into two groups: the AX group included 55 patients with previous axillary lymph node dissection; the non-AX group included 69 patients with previous SLNB and 12 patients with no axillary surgery. The whole breast irradiation (RT) after initial surgery had performed in 17 patients in the AX group and 27 patients in the non-AX group.

Results: Lymphatic drainage was visualized in 80% of the AX group and 95% of the non-AX group (P < 0.01). The visualization rate of lymphatic drainage was associated with the number of removed lymph nodes in prior surgery. In the non-AX group, lymphatic drainage was visualized in 96% of patients without RT and 93% with RT. Lymphatic drainage was observed at the ipsilateral axilla in 98% of patients without RT and in 64% with RT (P < 0.0001). Aberrant drainage was significantly more common in patients with RT than without RT (60% vs. 19%, P < 0.001); it was observed mostly to the contralateral axilla (52% vs. 2%, P < 0.0001). In the AX group, patients with previous RT showed decreased lymphatic drainage to the ipsilateral axilla compared to those without RT (29% vs. 63%, P < 0.05) and increased aberrant drainage to the contralateral axilla (64% vs. 5%, P < 0.0001).

Conclusion: Lymphatic drainage patterns altered in re-SLNB in patients with IBTR and previous ALND and RT were associated with alterations in lymphatic drainage patterns.

Keywords: Breast cancer, Lymphoscintigraphy, Aberrant lymphatic drainage, Sentinel lymph node biopsy, Whole breast irradiation, Ipsilateral breast tumor recurrence, Contralateral axilla

Background

While sentinel lymph node biopsy (SLNB) is a well-established procedure for patients with clinically node-negative primary breast cancer [1–4], established guidelines for the management of axillary lymph nodes in patients developing ipsilateral breast tumor recurrence (IBTR) are lacking.

It is known that a sentinel lymph node (SLN) is sometimes observed in extra-axillary regions of IBTR cases because lymphatic drainage patterns are altered by previous treatments, such as axillary surgery and irradiation of the breast [5–8]. Therefore, assessment of the ipsilateral axilla alone may not be sufficient for staging IBTR.

According to a report on SLNB for patients with primary breast cancer, the visualization rate of lymphatic drainage was 97%, and lymphatic drainage was mainly observed to the ipsilateral axilla (96%) [9]. In a small study, aberrant drainage was reported to the internal mammary chain (IMC) (22%), intramammary region
(7%), subclavicular region (3%), supraclavicular region (0.5%), and interpectoral region (2%) [9]. In contrast, a meta-analysis of re-operative SLNB (re-SLNB) for IBTR revealed a success rate of 71% for lymphatic mapping, markedly lower than that of SLNB in patients with primary breast cancer [10]. Aberrant drainage was observed in 43% of these patients, a much higher frequency than in patients with primary breast cancer. Although it is well known that previous axillary lymph node dissection (ALND) decreases the identification rate of SLNs for IBTR and increases aberrant drainage [5–7, 11], the impact of previous radiotherapy (RT) on re-SLNB remains largely unknown.

Because re-SLNB may provide useful information in determining adjuvant treatment for IBTR, we have performed re-SLNB for IBTR, using radioisotope techniques and preoperative lymphoscintigraphy to stage IBTR. The aim of this retrospective study was to evaluate lymphatic drainage patterns in re-operative SLNs (re-SLNs) in association with prior local therapy in patients with IBTR.

Methods
The institutional clinical database was used to identify patients who developed IBTR and underwent re-SLNB between April 2005 and December 2016. The ethical review committee of the institute approved this study protocol (No.2018–1222). Informed consent was obtained from all individual participants included in the study. Patients who underwent re-SLNB without preoperative lymphoscintigraphy, those with synchronous or metachronous bilateral breast cancer, and those lacking detailed information on previous surgeries were excluded. None of the patients had clinically metastatic lymph nodes, as examined by preoperative ultrasound. Fine needle aspiration cytology was performed if node metastasis was suspected by ultrasound.

The day before surgery, total 55.5 MBq (1.5 mCi) Tc-99 m phytate was injected at two intradermal sites at the tumor and at two peritumoral sites. Static images were obtained 1 h after the injection from 3 projections (anterior, 30 degrees anterior-oblique, and 60 degrees anterior-oblique views). Hot spots on the lymphoscintigram were regarded as re-SLNs. SPECT/CT was also performed in a subset of patients.

Patients were categorized into two groups according to their previous axillary surgeries: the non-AX group included patients with SLNB and no previous axillary surgery, and the AX group included those with ALND. Patients were further categorized based on the use of previous adjuvant RT.

A chi-squared test was applied to evaluate differences in lymphatic drainage patterns between the AX group and the no RT group. The Mann-Whitney test was used to compare the number of removed nodes between different groups. The log-rank test was used to compare the disease-free interval (DFI), the interval from primary surgery to the diagnosis of IBTR, between the patients whose lymphatic drainage was visualized on lymphoscintigraphy and those whose lymphatic drainage was not visualized. GraphPad Prism v.5.04 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. A two-sided P value of < 0.05 was considered statistically significant.

Results
Characteristics of patients
Between April 2005 and December 2016, 277 patients were identified who developed IBTR and underwent re-SLNB. Of the 277 patients, 141 were excluded according to the exclusion criteria, with 136 patients remaining in the analysis. The characteristics of the 136 patients are

| Characteristic | Value |
|---------------|-------|
| Ipsilateral breast tumor recurrence | |
| Median age (years old) | 55 (30–79) |
| Median disease-free interval (months) | 67 (10–233) |
| Clinical T stage | |
| Tis | 30 |
| T1 | 90 |
| T2 | 15 |
| T3 | 1 |
| Median follow-up period (months) | 141 (32–315) |
| At primary surgery | |
| Median age (years old) | 47 (22–76) |
| Clinical T stage of primary breast cancer | |
| Tis | 23 |
| T1 | 72 |
| T2 | 34 |
| T3 | 5 |
| unknown | 2 |
| Surgery for axilla | |
| no axillary surgery | 12 |
| SLNB | 69 |
| ALND | 55 |
| Adjuvant radiotherapy (RT) | |
| Without RT | 92 |
| With RT | 44 |

*a* Disease-free interval: the interval from primary surgery until the day ipsilateral breast tumor recurrence was diagnosed  
*b* SLNB: sentinel lymph node biopsy  
*c* ALND: axillary lymph node dissection
shown in Table 1. Median age at IBTR was 55 years. The median DFI was 67 months. Median follow-up period from the day of surgery for IBTR was 141 months.

Median age at primary surgery was 47 years. All patients had undergone breast-conserving surgery for their primary breast cancer. Sixty-nine and 55 patients had undergone SLNB and ALND, respectively, and 12 patients had no previous axillary surgery. Median number of lymph nodes removed at the primary surgery was 2 (1–6) in patients who had undergone SLNB and 20 (8–34) in patients who had undergone ALND. RT after breast-conserving surgery was performed in 44 patients. The whole breast irradiation dose was 42.5–50Gy with or without a boost dose of 10–16Gy in tumor beds. RT was not performed when surgical margins were entirely free of cancer, as confirmed by a precise pathological examination according to our institutional treatment protocol [12].

**Visualization of lymphatic drainage patterns on lymphoscintigraphy**

Preoperative lymphoscintigraphy identified at least one SLN, defined as re-SLN, in 121 (89%) of the 136 patients (Table 2). Lymphatic drainage was visualized at the ipsilateral axilla in 74%. Some patients showed multiple patterns of lymphatic drainage. Aberrant drainage was visualized in five regions: IMC, supraclavicular, intramammary, contralateral axilla, and contralateral IMC (Table 2). A representative case of aberrant drainage is shown in Fig. 1. DFI was shorter in patients whose lymphatic drainage was visualized on lymphoscintigraphy compared with patients whose lymphatic drainage was not visualized (60 vs. 129 months, P < 0.05). No difference in visualization rate was observed according to hormone receptor status and HER2 status for both primary cancer and IBTR (Table 3).

**Table 2** Lymphatic drainage patterns in all 136 patients with IBTR*

| Visualization on lymphoscintigraphy | N = 136 |
|-------------------------------------|---------|
| Yes                                 | 121 (89.0%) |
| No                                  | 15 (11.0%) |
| Lymphatic drainage patterns         |         |
| Ipsilateral axilla                  | 90 (74.4%) |
| Aberrant drainage                   | 57 (47.1%) |
| Internal mammary chain (IMC)        | 36 (29.8%) |
| Contralateral axilla                | 25 (20.7%) |
| Intramammary                       | 9 (7.4%)  |
| Supraclavicular                     | 2 (1.7%)  |
| Contralateral IMC                   | 1 (0.8%)  |

Lymphatic drainage was visualized in 121 of 136 patients. Lymphatic drainage to ipsilateral axilla was visualized in 74% of patients. Aberrant drainage was visualized in five regions: internal mammary chain (IMC), supraclavicular, intramammary, contralateral axilla, and contralateral IMC.

*IBTR ipsilateral breast tumor recurrence

**Impact of axillary surgery on lymphatic drainage patterns**

Lymphatic drainage patterns were compared according to previous axillary surgeries. The visualization rate of lymphatic drainage was higher in the non-AX group (95%) than in the AX group (80%) (P < 0.01) (Table 4). The visualization

---

![Fig. 1 Lymphoscintigraphy and SPECT/CT images of aberrant lymphatic drainages. (A) Lymphatic drainages were visualized at the contralateral axilla (arrow a) and the ipsilateral internal mammary chain (IMC) (arrow b) in a case with left IBTR. SPECT/CT revealed hot spots at the right axillary region (B) and the left IMC (C).](image-url)
rate was associated with the number of lymph nodes which had been removed in the prior surgery (Table 5). The median number of removed lymph nodes in the prior surgery was fewer in patients whose lymphatic drainage was visualized on lymphoscintigraphy compared with patients whose lymphatic drainage was not visualized (8 vs. 16 nodes, \( P < 0.05 \)). Lymphatic drainage was visualized in all 12 patients who had not undergone previous axillary surgery (Table 5). The visualization rate was markedly low (71%) in patients in whom 20 or more lymph nodes had been removed in prior surgery (Table 5).

Lymphatic drainage was visualized at the ipsilateral axilla in 87% of patients in the non-AX group and in 52% in the AX group \( (P < 0.001 \), Table 4). Aberrant drainage was visualized significantly more frequently in the AX (75%) than in the non-AX (33%) group \( (P < 0.0001 \). Lymphatic drainage was visualized at the internal mammary chain (IMC) in 16% of the non-AX group and 55% of the AX group \( (P < 0.001 \). Although axillary dissection had been performed in the AX group, re-SLNs were visualized in the ipsilateral axilla in 52% of patients: at level I and II of the axillae in seven patients, in the Rotter space in ten patients, and at level III of the axilla in three patients. In three patients in the non-AX group, re-SLNs that were visualized by lymphoscintigraphy failed to be identified during surgery because of the poor responses of the gamma-ray detection probe.

Impact of adjuvant radiotherapy on lymphatic drainage patterns
In the non-AX group, lymphatic drainage was visualized in 96% of patients without RT and 93% of those with RT.

| Table 3 Visualization on lymphoscintigraphy according to hormone receptor and HER2 status of primary tumor and IBTR |
| --- |
| **Visualization on lymphoscintigraphy**<br>\((N = 136)\) | Yes | No | \( P \) |
| **a. Primary breast cancer**<br>ER\(^a\) | | | |
| Positive | 54 | 3 | ns\(^d\) |
| Negative | 25 | 6 | |
| DCIS\(^b\) | 26 | 2 | |
| unknown | 16 | 4 | |
| PgR\(^c\) | | | |
| Positive | 46 | 5 | ns |
| Negative | 32 | 4 | |
| DCIS | 26 | 2 | |
| Unknown | 17 | 4 | |
| HER2 | | | |
| 3+ | 8 | 0 | ns |
| 2+ | 5 | 0 | |
| 1+, 0 | 40 | 6 | |
| DCIS | 26 | 2 | |
| Unknown | 42 | 7 | |
| **b. Ipsilateral breast tumor recurrence**<br>ER | | | |
| Positive | 64 | 10 | ns |
| Negative | 26 | 2 | |
| DCIS | 29 | 2 | |
| Unknown | 2 | 1 | |
| PgR | | | |
| Positive | 46 | 7 | ns |
| Negative | 44 | 5 | |
| DCIS | 29 | 2 | |
| unknown | 2 | 1 | |
| HER2 | | | |
| 3+ | 10 | 0 | ns |
| 2+ | 0 | 0 | |
| 1+, 0 | 78 | 12 | |
| DCIS | 29 | 2 | |
| Unknown | 4 | 1 | |

The visualization on lymphoscintigraphy was not associated with hormone receptor status and HER2 status of both primary cancer and IBTR

\( ^a \) ER: estrogen receptor

\( ^b \) DCIS: ductal carcinoma in situ

\( ^c \) PgR: progesterone receptor

\( ^d \) ns: no significant difference

| Table 4 Lymphatic drainage patterns according to previous axillary surgery |
| --- |
| **Previous axillary surgery** | **non-AX group\(^a\)** | **AX group\(^b\)** | \( P \) value |
| **Visualization on lymphoscintigraphy** | | | |
| Yes | 77 (95.1\%) | 44 (80.0\%) | < 0.01 |
| No | 4 (4.9\%) | 11 (20.0\%) | |
| **Lymphatic drainage patterns** | | | |
| Ipsilateral axilla | 67 (87.0\%) | 23 (52.2\%) | < 0.001 |
| Aberrant drainage | 25 (32.5\%) | 33 (75.0\%) | < 0.0001 |
| Internal mammary chain (IMC) | 12 (15.6\%) | 24 (54.5\%) | < 0.001 |
| Contralateral axilla | 14 (18.2\%) | 11 (25.0\%) | ns\(^c\) |
| Intramammary | 6 (7.8\%) | 3 (6.8\%) | ns |
| Supraclavicular | 0 (0\%) | 2 (4.5\%) | ns |
| Contralateral IMC | 1 (1.3\%) | 0 (0\%) | ns |

Lymphatic drainage patterns were compared among the 136 patients according to previous axillary surgeries. The visualization rate of re-SLNs in the non-AX group was higher than in the AX group. Aberrant drainages were visualized more frequently in the AX group than in the non-AX group. Whereas re-SLNs were visualized at the ipsilateral axilla in about 87% of the non-AX group, drainage to the ipsilateral axilla was significantly decreased and an alternative aberrant drainage pattern to the internal mammary chain was significantly increased in the AX group

\( ^a \) non-AX group: patients with previous SLNB and no previous axillary surgery

\( ^b \) AX group: patients with previous axillary lymph node dissection

\( ^c \) ns: no significant difference
Re-SLNs were visualized at the ipsilateral axilla in 98% of the patients without RT and in 64% of those with RT ($P < 0.0001$, Table 6a). Aberrant drainage was significantly more frequent in patients with RT (60%) than in those without RT (19%) ($P < 0.001$). Notably, more than half (52%) of patients with RT showed aberrant drainage to the contralateral axilla, whereas only 2% of those without RT did ($P < 0.0001$). No re-SLNs were visualized in the supraclavicular region in the non-AX group.

In the AX group, lymphatic drainage was visualized in 82% of patients with RT and 79% of those without RT (Table 6b). Aberrant drainage to the contralateral axilla was observed in nearly two-thirds (64%) of patients with RT but in 5% of those without RT ($P < 0.0001$, Table 6b).

**Discussion**

The present study revealed that the previous local treatment, not only axillary surgery but also RT, had impact on lymphatic drainage patterns in patients with IBTR. First, we confirmed the impact of previous axillary surgery on lymphatic drainage patterns. Next, we demonstrated that previous RT resulted in aberrant lymphatic drainage in 60% of patients in the non-AX group and in 93% in the AX group.

We found that the visualization rate of re-SLN was almost the same regardless of previous RT while it was reduced by axillary surgery (Tables 4, 6). In addition, RT reduced the ipsilateral axillary drainage from 98 to 64% and increased the aberrant drainage, especially to the contralateral axilla both in the AX group and in the non-AX groups. There were a few studies that examined the impact of RT on lymphatic drainage patterns and showed that RT had no effect on the identification rate of re-SLNs, in concordance with our study [5, 13]. Interestingly, in a study with 22 patients with breast cancer who had previously undergone mantle field radiation for Hodgkin’s lymphoma, the detection rate of SLNs was 86%, which was less than that in previously untreated patients with breast cancer (97%) [14]. The visualization rate of SLNs at the ipsilateral axilla was lower than that in patients with previously untreated breast cancer (86% vs. 92%), and SLNs were more often found outside the axilla (41% vs. 33%), especially at the IMC (32% vs. 21%) [14]. The discrepancy between our results and those of the patients receiving mantle field irradiation could be attributed to the difference in the irradiated fields and doses. In the study of mantle field radiation, the lymphatic regions in the neck, bilateral axilla, and mediastinum received a radiation dose of 36–40 Gy [14]. The medial and upper outer quadrants of the breast were also exposed to radiation. In contrast, the whole breast irradiation dose was 42.5–50Gy in the present study, and some patients were also given a boost dose of 10–16Gy in tumor beds. Considering that lymphatic drainage had been damaged by irradiation and aberrant lymphatic drainage did not involve the irradiated area, it was understandable that lymphatic drainage to the IMC increased after patients received mantle field irradiation and that lymphatic drainage to the contralateral axilla increased in those with previous whole breast irradiation.

According to our results, in patients with IBTR with previous SLNB and non-RT, lymphatic drainage remains mostly in the ipsilateral axilla, and these patients will be suitable for re-SLNB. On the other hand, re-SLNs were visualized at the contralateral axilla in more than 20% of the whole population (Table 2). Although there are some reports showing the feasibility of the re-SLNB procedure [7, 15–18], the clinical significance of re-SLNB has not yet been confirmed. In addition, it is further complicated in cases with aberrant SLNs. Metastasis to the contralateral axilla is regarded as distant metastasis in primary breast cancer [19], but in patients with IBTR, the
In deciding adjuvant treatment for IBTR [21]. Further pathological results in contralateral SLN may be useful of contralateral SLN and positive contralateral SLN, [20]. Although there are no guidelines for management node if re-SLNs are identified in the contralateral axilla may be considered a regional lymph contralateral axilla may be considered a regional lymph node if re-SLNs are identified in the contralateral axilla [20]. Although there are no guidelines for management of contralateral SLN and positive contralateral SLN, pathological results in contralateral SLN may be useful in deciding adjuvant treatment for IBTR [21]. Further studies to clarify the clinical significance of aberrant SLNs are required.

The major limitation of this study is the retrospective design with a small number of patients. In particular, the number of patients who had received previous RT was small and not enough to make any conclusion on the impact of RT on lymphatic drainage patterns. In addition, this study focuses only on lymphatic drainage patterns and does not examine the success rate of SLNB or pathological results of re-SLNs. Thus, the clinical significance of re-SLN examination is not clear. Another limitation is the lack of information on patient outcomes. It is important to examine the clinical outcomes of patients in association with treatment, including surgical procedures to determine the optimal treatment strategy. This is especially important in patients with aberrant lymphatic drainage.

### Table 6 Lymphatic drainage patterns according to previous radiotherapy

|                  | Without RT | With RT | P value |
|------------------|------------|---------|---------|
| **Visualization on lymphoscintigraphy** |            |         |         |
| Yes              | 52 (96.3%) | 25 (92.6%) | ns      |
| No               | 2 (3.7%)   | 2 (7.4%)  |         |
| **Lymphatic drainage patterns** |            |         |         |
| Ipsilateral axilla | 51 (98.1%) | 16 (64.0%) | < 0.001 |
| Aberrant drainage | 10 (19.2%) | 15 (60.0%) | < 0.001 |
| Internal mammary chain (IMC) | 7 (13.5%) | 5 (20.0%) | ns      |
| Contralateral axilla | 1 (1.9%)  | 13 (52.0%) | < 0.001 |
| Intramammary      | 4 (7.7%)   | 2 (8.0%)  | ns      |
| Supraclavicular   | 0 (0%)     | 0 (0%)   | ns      |
| Contralateral IMC | 0 (0%)     | 1 (40.0%) | ns      |

**Notes:**
- a) non-AX group
- b) AX group

**Abbreviations**
- ALND: Axillary lymph node dissection
- DFI: Disease-free interval
- IBTR: Ipsilateral breast tumor recurrence
- IMC: Internal mammary chain
- SLNB: Sentinel lymph node biopsy
- RT: Radiotherapy
- SLN: Sentinel lymph node
- re-SLNs: Re-operative sentinel lymph node biopsy

**Acknowledgements**
We thank all staffs working for the Breast Oncology Center of Cancer Institute Hospital of JFCR. We also express our gratitude to our data manager, Rie Gokan for her support.

**Authors’ contributions**
Study concepts and study design: TI. Data acquisition: AS, TS, FK, KK, AO. Quality control of data and algorithms: TS, MK, RH, FA. Data analysis and interpretation: AS, TS, TI. Manuscript editing: AS, TS, MT, TU. Manuscript review: TU, SO. All authors read and approved the final manuscript.

**Funding**
This study received no funding.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**
Informed consent was obtained from all individual participants included in the study. The ethical review committee of the Cancer Institute Hospital of Japanese Foundation for Cancer Research approved this study protocol (No.2018–1222).

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1. Department of Breast Surgical Oncology, Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan.
2. Department of Breast and Endocrine Surgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
3. Division of Gene regulation, Institute of Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku,
References

1. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.

2. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006; 98:599–609.

3. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 104:6–16.

4. Schrenk P, Shamiyeh A, Wayand W. Sentinel lymph-node biopsy compared to axillary lymph-node dissection for axillary staging in breast cancer patients. Eur J Surg Oncol WB Saunders. 2001;27:378–82.

5. Port ER, Garcia-Etienne CA, Park J, et al. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol. 2007;14:209–14.

6. van der Ploeg IMC, Oldenburg HSA, Rutgers EJT, et al. Lymphatic drainage patterns from the treated breast. Ann Surg Oncol. 2010;17:1069–75.

7. Uth CC, Christensen MH, Oldenburg MH, et al. Sentinel lymph node dissection in locally recurrent breast cancer. Ann Surg Oncol. 2015; 22:2526–31.

8. Koizumi M, Koyama M, Tada K, et al. The feasibility of sentinel node biopsy in the previously treated breast. Eur J Surg Oncol WB Saunders. 2008;34:365–8. Available from.

9. Estourgie SH, Nieweg OE, Valdés Olmos RA, et al. Lymphatic drainage patterns from the breast. Ann Surg. 2004;239:232–7.

10. Maaskant-Braat AJG, Voogd AC, Roumen RMH, et al. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2013;138:13–20.

11. Ahmed M, Baker R, Rubio IT. Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer. BJN Wiley & Sons, Ltd. 2016; 103:1579–88.

12. Sakai T, Iwase T, Teruya N, et al. Surgical excision without whole breast irradiation for complete resection of ductal carcinoma in situ identified using strict, unified criteria. Am J Surg Oncol. 2017;214:111–6.

13. Intra M, Trifirò G, Galimberti V, et al. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. BJS. 2007;94:1216–9.

14. van der Ploeg IMC, Russell NS, Nieweg OE, et al. Lymphatic drainage patterns in breast cancer patients who previously underwent mantle field radiation. Ann Surg Oncol. 2009;16:2295–9.

15. Intra M, Viale G, Vila J, et al. Second axillary sentinel lymph node biopsy for breast tumor recurrence: experience of the European Institute of Oncology. Ann Surg Oncol. 2015;22:2372–7.

16. Ugras S, Matsen C, Eaton A, et al. Reoperative sentinel lymph node biopsy is feasible for locally recurrent breast cancer, but is it worthwhile? Ann Surg Oncol. 2016;23:744–8.

17. Karanlik H, Ozgur I, Kilic B, et al. Sentinel lymph node biopsy and aberrant lymphatic drainage in recurrent breast cancer: findings likely to change treatment decisions. J Surg Oncol. 2016;114:796–802.

18. Maaskant-Braat AJG, Roumen RMH, Voogd AC, et al. Sentinel node and recurrent breast cancer (SNARB): results of a Nationwide registration study. Ann Surg Oncol. 2013;20:620–4.

19. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.

20. Moosssorff M, Vugts G, Maaskant-Braat AJG, et al. Contralateral lymph node recurrence in breast cancer: regional event rather than distant metastatic disease. A systematic review of the literature. Eur J Surg Oncol. 2015;41:1128–36.

21. Lizarraga IM, Scott-Conner CEH, Muzahir S, et al. Management of Contralateral Axillary Sentinel Lymph Nodes Detected on Lymphoscintigraphy for breast Cancer. Ann Surg Oncol. 2013;20:3517–22.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.